Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL
NCT02656147
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
48
Enrollment
INDUSTRY
Sponsor class
Conditions
Leukemia
Lymphoma
Interventions
BIOLOGICAL:
Anti-CD19-CAR γδT
Sponsor
Beijing Doing Biomedical Co., Ltd.